Email Updates

You are here

AVAC in the News

  • While global attention has fixated on the coronavirus, the forty-year long fight against HIV, which has claimed 33 million lives, is seeing new breakthroughs in preventive tools. New discoveries of “broadly neutralizing antibodies” as well as novel regimens of pre-exposure prophylaxis (PrEP), could strengthen the world’s toolbox to prevent the disease, announced the International AIDS Society (IAS) at the opening of the 4th HIV Research for Prevention Conference.

    January 27, 2021
    Antibody Related Research, PrEP
    Health Policy Watch
  • HIV PrEP uptake has increased sixfold globally in the last 4 years but remains short of the UNAIDS target of 3 million users, according to data reported during the HIV Research for Prevention virtual conference.

    January 26, 2021
    Healio
  • “The enormity of the problem is how I keep going,” Dr Anthony Fauci told a meeting of global health journalists yesterday. “I haven’t had a single day off since 20th January last year, but the necessity of dealing with the COVID epidemic is an anaesthetic against fatigue.”

    January 14, 2021
    aidsmap
  • Sports teams have faced intense blowback since the spring over the perception that they have received special treatment in a pandemic. Now some public health experts are weighing a counterintuitive idea for how they could help end it.

    December 6, 2020
    General
    Wall Street Journal
  • We can now see a light at the end of the COVID-19 tunnel, thanks to a growing amount of positive news on vaccines in development. There are many COVID-19 vaccines in the pipeline, and most—including the three that are currently the farthest along in development (one by Moderna, one by PFizer/BioNTech, and one by AstraZeneca/Oxford)—do not present any concern when it comes to potential HIV risk.

    December 2, 2020
    General
    The Body
  • Four COVID jabs’ efficacy results have been released within less than a year after the trials had started. But this is far from the norm. Researchers have been working on HIV vaccines for over three decades — and we still don’t have one. Here’s why.

    December 1, 2020
    Bhekisisa
  • The dark days of the HIV pandemic are over, but patients still face social stigma and emotional distress that can push them to stop treatment or even into a deep depression. Hear it first-hand from people who’ve experienced it.

    November 30, 2020
    General
    Bhekisisa
  • Three distinct therapeutic modalities (combination therapies, ex-vivo gene therapy, and in-vivo gene therapy) for a target product profile for an HIV cure were identified. Using a process of expert face-to-face consultation and an online Delphi consultation, we found a high degree of agreement regarding the criteria for the optimum target product profile. Although the minimum attributes for a cure were debated, the broad consensus was that an acceptable cure need not be as safe and effective as optimally delivered antiretroviral therapy.

    November 30, 2020
    Lancet HIV
  • We propose steps to plan for an HIV cure now, including defining a target product profile and establishing the HIV Cure Africa Acceleration Partnership (HCAAP), a multidisciplinary public-private partnership that will catalyse and promote HIV cure research through diverse stakeholder engagement. HCAAP will convene stakeholders, including people living with HIV, at an early stage to accelerate the design, social acceptability, and rapid adoption of HIV-cure products.

    November 30, 2020
    Lancet HIV
  • Each week, good news about vaccines or antibody treatments surfaces, offering hope that an end to the pandemic is at hand. And yet this holiday season presents a grim reckoning. The United States has reached an appalling milestone: more than one million new coronavirus cases every week. Hospitals in some states are full to bursting. The number of deaths is rising and seems on track to easily surpass the 2,200-a-day average in the spring, when the pandemic was concentrated in the New York metropolitan area.

    November 30, 2020
    General
    New York Times

Pages